Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery

Gynecologic Oncology

Volumn 96, Issue 2, 2005, Pages 341-348

  Wang, Minghui ^a,b,c,d   Hemminki, Akseli ^a,b,c,d,e,f   Siegal, Gene P ^b,g   Barnes, Mack N ^h   Dmitriev, Igor ^a,b,c,d   Krasnykh, Victor ^a,b,c,d   Liu, Bin ^a,b,c,d   Curiel, David T ^a,b,c,d   Alvarez, Ronald D ^h  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c Kentucky   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF HELSINKI   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adenoviruses; Neutralizing antibody; RGD 4C

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENE TARGETING; GENE TRANSFER; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; VIRUS NEUTRALIZATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; CAPSID PROTEINS; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; LUCIFERASES; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; OVARIAN NEOPLASMS;

EID: 12344257588     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.09.063     Document Type: Article

References (37)

1. Human gene marker/therapy clinical protocols (complete updated listing) Hum. Gene Ther. 12 2001 2251 2337
2. N. Chirmule, K. Propert, S. Magosin, Y. Qian, R. Qian, and J. Wilson Immune responses to adenovirus and adeno-associated virus in humans Gene Ther. 6 1999 1574 1583
3. A. Hemminki, M. Wang, R.A. Desmond, T.V. Strong, R.D. Alvarez, and D.T. Curiel Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy Hum. Gene Ther. 13 2002 1505 1514
4. B. Breyer, W. Jiang, H. Cheng, L. Zhou, R. Paul, and T. Feng Adenoviral vector-mediated gene transfer for human gene therapy Curr. Gene Ther. 1 2001 149 162
5. M.M. Burcin, G. Schiedner, S. Kochanek, S.Y. Tsai, and B.W. O'Malley Adenovirus-mediated regulable target gene expression in vivo Proc. Natl. Acad. Sci. U. S. A. 96 1999 355 360
6. K.J. Fisher, H. Choi, J. Burda, S.J. Chen, and J.M. Wilson Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis Virology 217 1996 11 22
7. W.K. O'Neal, H. Zhou, N. Morral, E. Aguilar-Cordova, J. Pestaner, and C. Langston Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery Hum. Gene Ther. 9 1998 1587 1598
8. M. Lusky, L. Grave, A. Dieterle, D. Dreyer, M. Christ, and C. Ziller Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3 J. Virol. 73 1999 8308 8319
9. S. Kochanek, P.R. Clemens, K. Mitani, H.H. Chen, S. Chan, and C.T. Caskey A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase Proc. Natl. Acad. Sci. U. S. A. 93 1996 5731 5736
10. M.I. Gorziglia, C. Lapcevich, S. Roy, Q. Kang, M. Kadan, and V. Wu Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3 J. Virol. 73 1999 6048 6055
11. P. Ostapchuk, and P. Hearing Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E J. Virol. 75 2001 45 51
12. J.G. Gall, R.G. Crystal, and E. Falck-Pedersen Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype J. Virol. 72 1998 10260 10264
13. R. Parks, C. Evelegh, and F. Graham Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration Gene Ther. 6 1999 1565 1573
14. T.J. Wickham Targeting adenovirus Gene Ther. 7 2000 110 114
15. E. Galanis, R. Vile, and S.J. Russell Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors Crit. Rev. Oncol. Hematol. 38 2001 177 192
16. A. Hemminki, N. Belousova, K.R. Zinn, B. Liu, M. Wang, and T.R. Chaudhuri An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression Mol. Ther. 4 2001 223 231
17. A. Kanerva, M. Wang, G.J. Bauerschmitz, J.T. Lam, R.A. Desmond, and S.M. Bhoola Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses Mol. Ther. 5 2002 695 704
18. L.J. Henry, D. Xia, M.E. Wilke, J. Deisenhofer, and R.D. Gerard Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli J. Virol. 68 1994 5239 5246
19. J.L. Blackwell, H. Li, J. Gomez-Navarro, I. Dmitriev, V. Krasnykh, and C.A. Richter Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid Hum. Gene Ther. 11 2000 1657 1669
20. I. Dmitriev, V. Krasnykh, C.R. Miller, M. Wang, E. Kashentseva, and G. Mikheeva An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism J. Virol. 72 1998 9706 9713
21. T.J. Vanderkwaak, M. Wang, J. Gomez-Navarro, C. Rancourt, I. Dmitriev, and V. Krasnykh An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches Gynecol. Oncol. 74 1999 227 234
22. G.J. Bauerschmitz, J.T. Lam, A. Kanerva, K. Suzuki, D.M. Nettelbeck, and I. Dmitriev Treatment of ovarian cancer with a tropism modified oncolytic adenovirus Cancer Res. 62 5 2002 1266 1270
23. H. Schmitz, R. Wigand, and W. Heinrich Worldwide epidemiology of human adenovirus infections Am. J. Epidemiol. 117 1983 455 466
24. A.H. Schulick, G. Vassalli, P.F. Dunn, G. Dong, J.J. Rade, and C. Zamarron Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity J. Clin. Invest. 99 1997 209 219
25. H. Gahery-Segard, V. Juillard, J. Gaston, R. Lengagne, A. Pavirani, and P. Boulanger Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts Eur. J. Immunol. 27 1997 653 659
26. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee Hum. Gene Ther. 13 2002 3 13
27. A. Hemminki, K.R. Zinn, B. Liu, T.R. Chaudhuri, R.A. Desmond, and B.E. Rogers In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus J. Natl. Cancer Inst. 94 2002 741 749
28. D.A. Muruve, M.J. Barnes, I.E. Stillman, and T.A. Libermann Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo Hum. Gene Ther. 10 1999 965 976
29. P.A. Piedra, G.A. Poveda, B. Ramsey, K. McCoy, and P.W. Hiatt Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors Pediatrics 101 1998 1013 1019
30. V. Mautner, and H.N. Willcox Adenovirus antigens: a model system in mice for subunit vaccination J. Gen. Virol. 25 1974 325 336
31. N. Willcox, and V. Mautner Antigenic determinants of adenovirus capsids. I. Measurement of antibody cross-reactivity J. Immunol. 116 1976 19 24
32. C.E. Wohlfart, U.K. Svensson, and E. Everitt Interaction between HeLa cells and adenovirus type 2 virions neutralized by different antisera J. Virol. 56 1985 896 903
33. C. Wohlfart Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms J. Virol. 62 1988 2321 2328
34. E. Norrby The relationship between the soluble antigens and the virion of adenovirus type 3. IV. Immunological complexity of soluble components Virology 37 1969 565 576
35. L. Philipson, K. Lonberg-Holm, and U. Pettersson Virus-receptor interaction in an adenovirus system J. Virol. 2 1968 1064 1075
36. S.C. Stevenson, M. Rollence, B. White, L. Weaver, and A. McClelland Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain J. Virol. 69 1995 2850 2857
37. B. Eiz, T. Adrian, and P. Pring-Akerblom Immunological adenovirus variant strains of subgenus D: comparison of the hexon and fiber sequences Virology 213 1995 313 320